KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
about
Mast Cell-Targeted Strategies in Cancer TherapySystemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcomeClinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of LiteratureTyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderHymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology.A meta-analysis of prognostic value of KIT mutation status in gastrointestinal stromal tumorsApplication of next generation sequencing in the diagnosis and management of mast cell leukemia.Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.Targeted Treatment Options in Mastocytosis.Case Report: Unusual Manifestation of KIT Negative Systemic Mastocytosis.Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma.Midostaurin: a magic bullet that blocks mast cell expansion and activation.Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.Mastocytosis - pathogenesis, clinical manifestation and treatment.Mastozytose - Pathogenese, Klinik und Therapie.Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.R634W KIT Mutation in an Adult With Systemic Mastocytosis.Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis.Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.Clonal eosinophil and mast cell diseases: different in the same way?
P2860
Q26743796-565EC76B-6BCE-4909-BAF2-6C5321B37AD8Q33168552-1468F9E2-C85B-45C6-BDC2-4C4FA329E2C6Q33431360-41E812EB-8BB4-4572-AFA9-0AA97996F0ABQ33670596-27C0080A-F3A4-4A6B-A957-59F8E8432079Q34495630-D1678855-35DA-4ECD-BC0E-944D9DE9756EQ34552564-73857287-E593-43DC-86DD-3C33C86ADA8AQ36210845-B0E2517C-7AAE-4CC6-B76E-1BE925EA55AFQ38543373-1AF22235-6BD3-4321-A50A-66FF9CF3252AQ38661465-C52905FA-AD1D-445B-BF52-177831973A31Q38698612-75741BCF-5097-4F27-BDA8-C494149B681BQ38736625-429E66DC-7F4F-4C37-B48F-DA0016F7BC78Q38777126-FA7E3D67-209D-4B6C-B879-7C66E7B1EC92Q38831928-4AC72AB1-7DE1-45B5-A286-F0944042A3E0Q39650027-2BDBC420-F11C-4345-A23D-DD467AB2F52CQ40063508-5DD73918-9C20-413E-81CA-8F16D43A7C88Q40241700-A24CD9FB-EF6A-4BC3-AA8B-336EF6834600Q41061871-136E490A-0208-4A09-AE6E-4185ED5A1CCFQ41533457-26A85633-A900-4714-B9D7-98B2ED96AAB7Q42703964-B0B0D7B1-A71B-4241-A675-9633656D5285Q47930594-BE3A7175-0BAD-485D-BB22-80ED24C68E0EQ48104415-02483F44-09AD-491D-A6AF-113A325A8F76Q50035104-6083C094-9ADD-4939-A29F-A6740929843CQ50122626-EAB4B7EA-4630-4E5A-B891-1D8688CE4CA9Q50122660-15628A24-9F7E-497E-B185-E51028D8150EQ52783857-3AC9EE29-26C8-420F-B964-380010FD5504Q53084383-673DC567-257A-4D06-8CE2-73D468E53A9CQ53284913-7D526BBD-7F7B-4665-9F10-3D3D9A1F0611Q53459692-7CA685EF-D5E6-4749-8DA5-B65FECDE26AEQ53691901-3D967E1A-0D4A-42D0-8DCC-D15ACDAA0F33Q55029786-EAAF8737-E06B-4CB9-8701-F8E08EA4702FQ55286285-B4302566-5B38-4B67-900D-71E5855F4A4DQ57216516-1F53E563-F5B1-43A9-BC0F-7BEFED6E3435
P2860
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@ast
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@en
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@nl
type
label
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@ast
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@en
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@nl
prefLabel
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@ast
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@en
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
KIT mutation analysis in mast ...... etence Network on Mastocytosis
@en
P2093
D D Metcalfe
L Escribano
S Broesby-Olsen
P2860
P2888
P304
P3181
P356
10.1038/LEU.2015.24
P407
P50
P577
2015-02-04T00:00:00Z
P6179
1039972295